Intas Allays Concerns Around Lucentis Biosimilar In India

Intas Pharmaceuticals has claimed that certain adverse events reported with its Lucentis biosimilar were not caused by “qualitative aspects” of the product and that physicians have since “very satisfactorily” used subsequent batches of the vascular endothelial growth factor inhibitor in India.